fashion -WSS

fashion

author：hotspot 2025-09-14 14:45:24 - browse：84

Five elderly people have been blinded in one eye by a severe side effect after receiving injections of a newly approved treatment for eye disease from Apellis Pharmaceuticals. The frequency of this side effect — a severe type of eye inflammation — is low but its cause remains unknown.

The new safety information related to the Apellis drug, called Syfovre, was presented Saturday by a committee of eye disease experts at the annual meeting of the American Society of Retinal Specialists (ASRS).

Apellis cooperated with the ASRS analysis but the company also announced its own internal review Saturday that found fewer cases of retinal occlusive vasculitis, a type of severe eye inflammation that blocks blood flow to the retina and can result in blindness. The rate of retinal occlusive vasculitis reported remains “very rare,” the company said, adding that there is no evidence linking the drug product or its manufacturing to the severe side effect.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： FDA approval of Sarepta Duchenne genetic therapy gives me hope
Next article： RSV shot was 90% effective at preventing hospitalizations in kids

WSS

Novo Nordisk gets FDA approval to tout heart benefits of Wegovy

With psoriasis trial ahead, Alumis raises $259 million

Readout Newsletter: Medeor's stem cell study, Moderna's stock dip

Live blog: Hearing on CRISPR

Lung cancer screening guidelines updated for cigarette smokers

DeepMind touts AlphaFold's new skills as protein folding AI models face off

Wikipedia

fashion

focus

Guidelines to prevent youth baseball injuries need more muscle

Air quality improving but still lags in Black, Hispanic communities

George Santos makes 1st court appearance after pleading not guilty to 13 counts

A deep dive into Applied Therapeutics’ data, and questions on Cassava

Continuity nursing helped my family in our darkest PICU moments

The Readout: Amylyx, Alumis, and Lundbeck drug updates

Walensky prepares to leave CDC — and Congress — behind

The Readout: Amylyx, Alumis, and Lundbeck drug updates

Walensky prepares to leave CDC — and Congress — behind

Just how do doctors, lawmakers, and the public define abortion?

hotspot

With psoriasis trial ahead, Alumis raises $259 million

Change Healthcare cyberattack prompts Medicare loan program

Key Senate panel to consider PBM, drug pricing reform package

All of Us, NIH's precision medicine initiative, gets a big boost

Inari Medical to buy amputation prevention company LimFlow

Novo Nordisk obesity pill bests Wegovy in early trial

knowledge

focus

focus

focus